All In Biotech

NDA 213498 · Vanda Pharms INC

Ponvory

Ponesimod · Oral · Sphingosine 1-phosphate Receptor Modulator

Novel

CDER novel approval, Mar 18, 2021: To treat relapsing forms of multiple sclerosis

Last checked: Nov 20, 2026Latest source record: Jun 5, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Mar 18, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

19

5 Phase 3, 2 recruiting

FAERS reports

438

166 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 13, 2026.

PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PONVORY is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1. Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ponesimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 18, 2021 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
3 products under this application
  • PONVORY · PONESIMOD 20MG · TABLET, ORAL · Prescription
  • PONVORY · PONESIMOD 20MG · TABLET, ORAL · Prescription
  • PONVORY · PONESIMOD 2MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ponesimod" as an intervention, any sponsor and status, largest first.

All 19 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue76
  • fatigue35
  • dizziness25
  • dyspnoea24
  • headache22
  • product use issue17
  • nausea14
  • covid-1913
  • drug ineffective13
  • pain12
  • hypoaesthesia11
  • somnolence11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20191
202134
2022135
202378
202429
202542
2026119

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ponvory (Ponesimod)

2024 spending

$6.4M

Beneficiaries

79

528 claims

Per beneficiary

$80,600

$313.15 per unit

View as table
YearSpending
2020$0
2021$568,668
2022$4,610,821
2023$8,307,094
2024$6,367,371

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 42 on PubMed

Sponsor: Vanda Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.